Markus Warmuth, Monte Rosa Therapeutics CEO
May 21, 2024 10:35 AM EDT
Financing

With a fresh $100M, Monte Rosa CEO de­tails plans to move sev­er­al mol­e­c­u­lar glues in­to the clin­ic

Andrew Dunn

Senior Biopharma Correspondent

Monte Rosa Ther­a­peu­tics CEO Markus War­muth ex­pects mol­e­c­u­lar glues to make up a new class of drugs with “al­most un­lim­it­ed po­ten­tial” in the long run …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times